This biotech company develops small-molecule targeted therapies for prevalent diseases, including cardio-metabolic conditions like diabetes and obesity. They utilize AI platforms to identify and advance novel therapeutics, aiming to provide affordable treatment alternatives in areas with high unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatment options for cardio-metabolic diseases like diabetes and obesity often come with high costs and limited accessibility, particularly in emerging markets and for patients with limited insurance coverage. Many patients lack access to innovative therapies, even after generic versions or biosimilars become available, due to continued high prices.
Solution
RenaissThera is developing affordable small-molecule therapies for prevalent diseases, focusing on cardio-metabolic conditions. The company leverages an AI platform to identify and develop novel therapeutics targeting validated pathways, offering cost-effective alternatives to expensive treatments. By focusing on small molecule NME-targeted therapies, RenaissThera aims to provide safer and effective alternatives that are currently inaccessible to a wider population. The company prioritizes indications prevalent in emerging markets with the potential to serve globally, addressing needs in both low-income countries and underserved populations in developed countries. Clinical studies are conducted in emerging markets to lower development costs, and global clinical studies are planned to facilitate parallel launches across target markets.
Target Audience
The primary target audience includes patients in emerging markets and underserved populations in developed countries who lack access to affordable and innovative therapies for cardio-metabolic diseases such as diabetes and obesity.
Features
- Focus on small molecule alternatives for validated novel pathways and targets.
- Utilizes a generative AI platform to accelerate target and drug discovery, identifying validated targets and novel molecules.
- Develops therapies in emerging markets to reduce development costs and serve a broader, low-income population.
- Focus on oral therapies that can be administered in outpatient settings, reducing the need for hospitalization and extensive monitoring.
- Pipeline includes small molecule GLP-1R agonists, GIPR agonists/antagonists, Apelin agonists, and combinations for diabetes and obesity.
- Aims to develop therapies with better safety profiles, requiring less monitoring, which is crucial in low-income countries with limited healthcare infrastructure.